Mind The Gap: Different Views Of Success May Drive Large Differences In Estimates Of Pharma Value

  
Generate a summary of this article
Listen to this article
Beta

The success rates of late-stage molecules may prove to be higher than current analyst estimates; historical data suggests the biopharma industry has been fairly resilient in its ability to deliver its R&D pipeline while adapting to challenges.

R&D productivity is often linked to return on investment (ROI), rates of return and company value. Growing concerns around the industry's productivity challenges have, not surprisingly, precipitated a good deal of research on what drives R&D productivity. These studies have found that, in addition to cost, one of the most significant performance levers within pharmaceutical R&D is the probability of obtaining regulatory approval for a new drug. The fates of late-stage drugs in particular have a significant impact on determining new product flow, which in turn drives the future performance and value of companies.

One key metric analysts and investors use when building models of drug firms' future financial performance is an estimation of...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

SpotifyApple PodcastsWebsite

More from Business Strategy

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 
• By Edwin Elmhirst and Lucie Ellis-Taitt

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

test carousel

 
• By Saba Afreen

test carousel-In-Vivo

Slow Progress: A Decade Of Cell Therapy In Japan

 
• By Lisa Takagi

After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.

More from In Vivo

XXXXtesting

 
• By Saba Afreen

XXXXtesting

In Vivo’s 2026 Rising Leaders At A Glance

 
• By Saba Afreen

Top 30 leaders: see the list of industry influencers highlighted in the sixth edition of In Vivo's Rising Leaders series.

InVivo-Innovation-Free: ‘Interview’ article that includes different Composer content

 
• By Nabil, Olga Zviezdicheva, Reed Miller, Mary Jo Laffler, Ian Schofield, João Andrés-Ruíz de la Fontaine-LeBlanc, Chloë Anastasía-Stojanović del Castillo-Ribeirão, and Nabil

To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.